Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Global cancer cases could reach nearly 35 million a year by 2050, without urgent action to improve cancer prevention, early diagnosis and access to treatment, according to the World Health Organization (WHO) Global Status Report on Cancer 2026.

The report warns that cancer remains the world's second leading cause of death, claiming more than 26,000 lives every day and nearly 10 million annually.

The report, jointly released by the WHO and the International Agency for Research on Cancer (IARC), warned that major inequalities in cancer prevention, diagnosis, treatment and supportive care continue to leave millions of people without access to life-saving services.

It also noted that ageing populations, population growth and persistent health inequalities are driving the cancer cases.

"Cancer is a deeply personal disease that touches nearly all of us. But whether a person survives cancer should never depend on where they were born or what they earn," said WHO Director-General Dr Tedros Adhanom Ghebreyesus.

"The inequities documented in this report are not inevitable; they are the consequence of choices, and they can be reversed through stronger and unified action."

Global Status Report on Cancer 2026: Key Findings

Also read: At 2026 NATO Summit, Trump's Neck Rash and Bruised Hand Draw Attention; White House Responds

Cancer survival varies sharply across countries

The report highlights major disparities in cancer outcomes.

• 87% of women diagnosed with breast cancer survive at least five years in high-income countries.
• In low-income countries, the five-year survival rate falls to around 42%.
• Fewer than one in three countries include comprehensive cancer care under universal health coverage.

Cancer places a heavy financial burden on families

Beyond its health impact, cancer also creates significant economic and emotional challenges.

• At least 45% of people living with cancer experience financial hardship.
• More than half report mental health challenges.
• Nearly all caregivers experience strain, including unpaid caregiving responsibilities and social isolation.

Read More: US Cyclospora Parasite Outbreak Nears 900 Cases: Experts Say Handwashing Key to Prevention

Which Regions Have the Highest Cancer Burden?

The report shows that the burden of cancer varies significantly across regions.

Asia

• Accounts for 50.7% of global cancer cases.
• Records 56.5% of cancer deaths worldwide.

Europe

Although home to only about 9% of the world's population, Europe accounts for:

• 21% of global cancer cases.
• 20% of global cancer deaths.

Africa

Many African countries continue to experience comparatively lower cancer incidence but disproportionately higher mortality because of delayed diagnosis and limited access to treatment.

Most Common Types of Cancer Worldwide

READ: Don't Ignore These Cancer Symptoms: Oncologist Shares The Early Warning Signs

According to the WHO report:

• Lung cancer remains the leading cause of cancer deaths globally.
• Among men, the most common cancers are:
  • Lung
  • Prostate
  • Colorectal
• Among women, the leading cancers are:
  • Breast
  • Lung
  • Colorectal

Nearly Four in Ten Cancer Cases Are Preventable

The report estimates that almost 40% of cancer cases worldwide are linked to preventable risk factors, including:

• Tobacco use
• Alcohol consumption
• High body weight
• Physical inactivity
• Human papillomavirus (HPV)
• Hepatitis B and Hepatitis C infections
• Helicobacter pylori infection

WHO's Recommendations to Improve Global Cancer Care

The WHO has urged governments, health organizations, researchers and the private sector to work together to strengthen cancer care through three broad priorities:

Better capabilities

• Integrate cancer control into universal health coverage.
• Invest in cancer prevention, early detection and the healthcare workforce.

Better protections

• Put people living with cancer and caregivers at the centre of health systems.
• Expand financial and social protection for affected families.

Better value

• Align cancer research and innovation with public health priorities.
• Ensure equitable access to effective, evidence-based cancer treatments worldwide.

Novo Nordisk, the maker of GLP-1 medicines like Ozempic and Wegovy, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections.

The Danish pharma company has partnered with Vivani Medical to evaluate an experimental long-acting GLP-1 implant (semaglutide) that could release the medication continuously for up to a year.

If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity.

What Is The Semaglutide Implant?

The implant, known as NPM-139, is a miniature device developed using Vivani's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period.

According to Vivani, the goal is to provide consistent drug delivery with once- or twice-yearly dosing, with the long-term ambition of supporting treatment that could last up to a year from a single implant. However, the technology is still in development.

Adam Mendelsohn, Ph.D., President and CEO of Vivani Medical said, “The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary.”

Also read: Wegovy Weight Loss Pill Available in UK Pharmacies From Today: All You Should Know

Why GLP-1 Implant Could Be Groundbreaking?

GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment by helping people lose significant amounts of weight while also improving blood sugar control. However, these medications require regular injections, which can affect long-term adherence.

Research has shown that many patients discontinue GLP-1 therapy within the first year because of factors like treatment fatigue, gastrointestinal side effects, cost, and the inconvenience of ongoing injections.

An implant capable of delivering semaglutide continuously for months together could help by reducing dosing frequency and maintaining more consistent drug levels.

The Rise Of GLP-1 Therapies In Obesity Treatment

The obesity drug market is rapidly evolving. With the advent of GLP-1 medications, the number of users who have tried this therapy is at an all-time high. According to Gallup's latest National Health and Well-Being Index, 11% of U.S. adults currently use a GLP-1 medication for weight loss. In 2024, this number was just 3%.

The survey also said that 15% of adults have tried a GLP-1 medication at some point, compared to the 6% from two years ago.

With the ever-increasing demand, researchers are investigating oral GLP-1 medicines, monthly injections, combination therapies, and now long-acting implants that could reduce the number of treatments patients need each year.

While the yearly semaglutide implant is still an experimental concept, Novo Nordisk's decision to evaluate the technology highlights growing industry interest in making obesity treatment simpler and easier for patients to maintain in the long run.

Last week, biohacker and longevity entrepreneur Bryan Johnson shared a shocking health update with his followers. He said that he has been diagnosed with Autoimmune Gastritis (AIG), a chronic autoimmune disease in which the immune system attacks the stomach lining. In an X post, he said, “My stomach is eating itself.”

After his post received millions of reactions, he shared his ambitious plan to treat his autoimmune gastritis.

How Is Bryan Johnson Planning To ‘Cure’ His Autoimmune Gastritis?

One of the most unusual aspects of Bryan’s AIG treatment plan is creating a miniature version of his immune system called ‘Bryan In A Dish'. He said that scientists will collect and cryopreserve (freeze) a large sample of his immune cells for two purposes.

First, researchers plan to recreate a miniature version of Johnson's immune system in a laboratory dish. This living model would allow scientists to test experimental drugs and personalized therapies directly on his own immune cells before administering them to him, potentially reducing risks while helping identify the most promising treatment.

Second, the frozen cells could preserve cellular material that may support future targeted rejuvenation or precision medicine therapies.

While scientists have long used “disease-in-a-dish" models to study diseases and drugs, Bryan’s “Bryan in a dish” goes a step further by creating a personalized immune system model using his own preserved cells to test experimental autoimmune treatments before they are used in his body.

Also read: At 2026 NATO Summit, Trump's Neck Rash and Bruised Hand Draw Attention; White House Responds

Other steps in his plan includes:

• Mapping the immune system:

Johnson plans to sequence one million of his immune cells to identify the specific T-cells that are mistakenly attacking his stomach lining.

• Capturing the rogue immune cells:

He will undergo another stomach biopsy to collect live tissue, allowing researchers to match the harmful T-cells with the immune cell mapping data.

• Building an early warning system

Johnson intends to have blood tests every two weeks and combine the results with wearable health data to detect disease flare-ups before symptoms appear. He said that this is essential as the condition presents without any symptoms.

• Develop precision therapies

After identifying the rogue immune cells, researchers will test personalized treatments designed to stop only those harmful cells while preserving the healthy immune system.

Bryan Johnson's Autoimmune Gastritis Diagnosis

Despite years of optimizing his body, Bryan’s Johnson’s autoimmune gastritis diagnosis shocked the internet. While his strict routines, meticulous diet, and million-dollar anti-ageing protocol continue to inspire millions, they also receive equal amounts of skepticism and criticism.

Johnson recently revealed that he had struggled with persistently low iron for nearly 11 years, despite taking supplements.

He said that a detailed evaluation confirmed autoimmune gastritis, an illness that damages the acid-producing cells of the stomach. The condition can impair absorption of iron and vitamin B12 and may increase the long-term risk of gastric cancer.

He also disclosed that he has autoimmune thyroid disease, suggesting that multiple autoimmune conditions may be interconnected in his case.